The present invention provides compounds of formula I that are useful as potent and selective inhibitors of 11-beta hydroxysteroid dehydrogenase 1. The present invention further provides a pharmaceutical composition which comprises a compound of Formula I, or a pharmaceutical salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. In addition, the present invention compositions containing these compounds for the treatment of metabolic syndrome, diabetes, hyperglycemia obesity, hypertension, hyperlipidemia, other symptoms associated with hyperglycemia, and related disorders. Formula I wherein G1 is methylene or ethylene; L is -(C1-C4)alkylene-, -S-, -CH(OH)-, or -O-; R0 is Formula II or Formula III and the other substituents are as defined in the claims.

The present invention provides compounds of formula I that are useful as potent and selective inhibitors of 11-beta hydroxysteroid dehydrogenase 1. The present invention further provides a pharmaceutical composition which comprises a compound of Formula I, or a pharmaceutical salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. In addition, the present invention provides compositions comprising compounds of formula I for the treatment of metabolic syndrome, diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, other symptoms associated with hyperglycemia, and related disorders. Formula (I) wherein, R0 is (II), or (III) G1 is methylene or ethylene; L is a divalent linking group selected from —(C1-C4) alkylene-, —S—, —CH(OH)—, or —O—; A is methylene, —S—, —O—, or —NH—; and the other substituents are as defined in the claims.

The present invention relates to pharmaceutical compositions based on antiinflammatory active ingredients and to the use thereof for the treatment of rheumatoid diseases. The compositions comprise lactalbumin hydrolysate or a fraction thereof. Substantially lower doses of the antiinflammatory drugs are thus possible than is conventionally necessary to achieve a particular antiinflammatory effect.

This invention provides new benzoxazepine compounds represented by the formula: Äwherein R stands for a lower alkyl group optionally substituted with a hydroxyl group, X stands for an optionally substituted carbamoyl group or an optionally substituted heterocyclic group having a deprotonatable hydrogen atom, R1 stands for a lower alkyl group and W stands for a halogen atomÜ having activities of lowering chlesterol-level and lowering trigluceride-level, and being useful for prophylaxis and therapy of hyperlipidemia.

Chemical patent from PubChem database. Patent Number: AT-E401321-T1. Title: Crystalline Forms of Chemical Compounds. Filing Date: 2005-11-09. Inventors: Anderson, Robert, Davis, Linda. Abstract: The invention provides novel crystalline forms of chemical compounds, characterized by specific X-ray powder diffraction patterns and thermal properti... IPC Classifications: C12N, C12P, A61K. This patent covers 18 claims related to 8 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.

A pharmaceutical composition comprising a pharmaceutically effective amount of a pharmaceutically active substance and a pharmaceutically acceptable carrier including a cationic excipient, wherein said cationic excipient is a labile ester of betaine and a lipophilic alcohol having at least one primary hydroxyl group. Also, the use of a labile ester of betaine and a lipophilic alcohol having at least a primary hydroxyl group as a cationic excipient in a carrier for a pharmaceutical composition comprising a pharmaceutically active substance.

The invention relates to a cytisine containing solid dosage form for oral administration. It helps achieve an even distribution of the active substance throughout the tablet mass. The resulting tablets possess high mechanical strength, high solubility of cytisine and good disintegration. This is achieved through appropriate lactose and microcrystal cellulose ratios and contents of the cytisine tablets.

Chemical patent from PubChem database. Patent Number: AT-E40106-T1. Title: Method of Treatment Using Chemical Compounds. Filing Date: 2006-06-16. Inventors: Martinez, Carlos, Thompson, Emily. Abstract: Methods for treating diseases using specific chemical compounds are provided, including dosing regimens and combination therapies for enhanced therape... IPC Classifications: C07D, C07F, A61K. This patent covers 34 claims related to 4 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.

A composition comprising a basic drug, a drug which forms a zwitterion, or a salt of either entity, admixed with a polymer selected from hydroxypropylmethylcellulose acetate succinate (HPMCAS), cellulose acetate trimellitate (CAT), cellulose acetate phthalate (CAP), hydroxypropylcellulose acetate phthalate (HPCAP), hydroxypropylmethyl-cellulose acetate phthalate (HPMCAP), and methylcellulose acetate phthalate (MCAP). The compositions having improved solubility, hence bioavailability, in the small intestine; Processes for testing such compositions, and methods of using such compositions. The compositions comprise the basic drug, zwitterion, or salt and one or more of the aforementioned polymers. The invention further relates to a method for increasing the bioavailability of a basic or a zwitterionic drug comprising co-administering the basic drug, the zwitterionic drug, or the salt, with one or more of the aforementioned polymers.

Chemical patent from PubChem database. Patent Number: AT-E401339-T1. Title: Novel Drug Delivery System. Filing Date: 2007-06-25. Inventors: Chen, Wei, Kumar, Raj, Williams, Sarah. Abstract: The present invention discloses a drug delivery system designed to provide targeted and sustained release of therapeutic agents, improving patient com... IPC Classifications: A61K, A61P, C07D. This patent covers 20 claims related to 3 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.